ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AARD / options
PMN (35) FLNA (38) NXTC (37) RMTI (23) ⌘ Pro Terminal →

Aardvark Therapeutics Inc. (AARD) Options Positioning, Max Pain & Unusual Sweeps

$1.20 -11.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.17

Aardvark Therapeutics Inc. (AARD) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $29.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AARD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AARD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Aardvark Therapeutics Inc. (NASDAQ: AARD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.20 (-11.76% 1D, market cap $29.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AARD ranks #693 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AARD compare to PMN and FLNA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AARD carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PMN (ProMIS Neurosciences Inc. (ON)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $29.7M) and FLNA (Filana Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, AARD leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AARD?
▼

Per AARD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001774857), Aardvark Therapeutics Inc. generated $175.6M in revenue (+175.3% YoY), -$57.6M in net income, and -$54.3M in free cash flow against $117.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.17 (-2.31%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$17 Bull$1 Base$1 Bear
📬 FREE AARD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AARD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY AARD SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 25.8 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$4.04-3.5% Next Q
Q2 (-2Q)
38
Grade E$3.90-66.7% Next Q
Q3 (-1Q)
36
Grade E$1.30-7.7% Next Q
Current
33
Grade E$1.20-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AARD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AARD currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.56) and Max Pain ($1.26) forces dealer call-delta covering toward $17.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AARD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AARD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AARD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AARD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AARD)

  • ✓Walkthrough of AARD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AARD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -77.23%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.44H $1.44L $1.20C $1.20VOL 467.6K
RES: $10.24SUP: $0.77SMA50: $4.56SMA200: $6.18
$11.23$8.44$5.65$2.86$0.06RES $10.24SUP $0.77$1.202026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AARD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AARD Butterfly Map → + Track AARD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +175.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AARD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AARD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AARD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AARD)

Health Care Rank #693 of 1015 ⚔️ PMN vs AARD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AARD vs. PMN, FLNA, NXTC, RMTI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Aardvark Therapeutics Inc. (AARD) ranks #693 by composite RQD confidence (33/100, grade E) and #798 by equity capitalization ($29.8M). Within this direct 5-issuer industry benchmark cohort, AARD leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. FLNA currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with AARD at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AARD ACTIVE
Aardvark Therapeutics Inc.
E 33/100 — — -35.0% -11.76% $29.8M Benchmark Subject
PMN
ProMIS Neurosciences Inc. (ON)
D- 35/100 — — -35.0% -9.37% $29.7M /pmn-vs-aard →
FLNA
Filana Therapeutics Inc.
D- 38/100 — — -35.0% -9.81% $30.0M /flna-vs-aard →
NXTC
NextCure Inc.
D- 37/100 — — -35.0% -9.75% $28.9M /nxtc-vs-aard →
RMTI
Rockwell Medical Inc.
E 23/100 — 16.9% -10.6% -2.26% $28.5M /rmti-vs-aard →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001774857 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aardvark Therapeutics Inc. (AARD) reported GAAP revenue of $175.6M (+175.3% vs. FY2024 revenue of $63.8M ) , GAAP net income of -$57.6M, operating cash flow of -$54.2M, and free cash flow of -$54.3M (-198.2% YoY). On the balance sheet, AARD closed FY2025 with $117.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $175.6M -$57.6M -$54.2M -$54.3M $117.2M —
FY2024 (FY) 2024-12-31 $63.8M -$20.6M -$18.1M -$18.2M $77.5M —

3. AARD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AARD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Aardvark Therapeutics Inc. (NASDAQ: AARD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.20 (-11.76% 1D, market cap $29.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AARD ranks #693 in composite RQD confidence.

How does AARD compare to PMN and FLNA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AARD carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PMN (ProMIS Neurosciences Inc. (ON)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $29.7M) and FLNA (Filana Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, AARD leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AARD?

Per AARD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001774857), Aardvark Therapeutics Inc. generated $175.6M in revenue (+175.3% YoY), -$57.6M in net income, and -$54.3M in free cash flow against $117.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AARD trading relative to its 50-day, 200-day, and 52-week technical levels?

AARD last traded at $1.20 (-11.76% on volume of 345,546 shares), positioning the stock -73.68% below its 50-day simple moving average ($4.56) and -80.58% below its 200-day simple moving average ($6.18). Across its 52-week range of $0.93 to $16.60, AARD sits at the 1.7% percentile with a 14-day RSI of 25.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.05 to $1.35).

Direct Sub-Reports: AARD RQD Cockpit AARD 12M Forecast AARD Earnings & Move AARD Dividends & DRIP AARD Insiders & 13F AARD Whale Options AARD Profit Sankey AARD News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

AARD — Aardvark Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Aardvark Therapeutics Inc. (AARD) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.20 (-11.76% 1D, market capitalization $29.8M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Aardvark Therapeutics Inc. (AARD) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Products, customers, and revenue model details are — The FY 2025 and FY 2024 financials report revenue of — in each period, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Aardvark Therapeutics Inc. (AARD) reported $175.6M in annual revenue (up from $63.8M in FY2024, +175.3% YoY) and -$57.6M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($63.8M revenue, -$20.6M net income) through FY2025, AARD scaled operating cash flow to -$54.2M and free cash flow to -$54.3M, backed by $117.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.93 – $16.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data. Investors should note that the absence of mapped links means this analysis cannot identify ripple effects from related companies.

  • Key Question #1: Can AARD sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $175.6M and free cash flow of -$54.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AARD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AARD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aardvark Therapeutics Inc. (AARD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AARD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AARD Bull vs. Bear Conversation Board — What's Your Call at $1.20?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AARD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AARD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $1.62 (+19.1%)
📌 Pinned Debate

A positive rating-upgrade headline to Buy appears in the recent news feed alongside a 2.5 Altman Z-Score.

Don't sleep on AARD's setup in Health Care. A positive rating-upgrade headline to Buy appears in the recent news feed alongside a 2.5 Altman Z-Score.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (33/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 33/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.36 and keeping dry powder in case we test $1.26.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $1.07 (-21.3%)
Spot @ $1.36

ROIC of -35%, 0% FCF yield, and a Piotroski F-Score of 2/9 point to continued cash burn and weak financial health.

Fading this rally in AARD at $1.36. ROIC of -35%, 0% FCF yield, and a Piotroski F-Score of 2/9 point to continued cash burn and weak financial health.. With a beta of 1.0 and the stock sitting at $1.36 (52-wk range $0.93–$16.60), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%